×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Advancing Endpoint Adjudication
Session Chair(s)
Jonathan Seltzer, MD, MA, MBA, FACC
Chief Scientific Officer
WCG, United States
CRO, sponsor, and agency perspectives on the evolution of clinical endpoint adjudication committees (EACs) will elucidate relevant definitions and emerging requirements substantiated by case studies and metrics from dozens of global programs/projects.
Learning Objective : Describe the rationale for convening an endpoint adjudication committee (EAC); Recognize the principal regulatory and practical considerations underlying a well-run EAC from CRO, sponsor, and agency perspectives; Identify and discuss how to apply at least three EAC best practices into clinical development.
Speaker(s)
Panelist
Douglas Burgener
Biofourmis, United States
Sr. Marketing Director
Panelist
Debra Montgomery, MSN, RN
Duke Clinical Research Institute, United States
eCRF Librarian, CDS III
Panelist
Nicole Pushlar
Boehringer Ingelheim Pharmaceuticals, Inc., United States
Clinical Scientist, Clinical Trial Management
Have an account?